about
Endoscopic and histologic characteristics of serrated lesionsEffective use of argon plasma coagulation in the treatment of severe radiation proctitis.[Specific carbohydrate malabsorption]Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature.Laparoscopic total colectomy: Does the indication influence the outcome?Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years.Enrichment of Circulating and Mucosal Cytotoxic CD8+ T Cells Is Associated with Postoperative Endoscopic Recurrence in Patients with Crohn's DiseaseClinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis.Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment.Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.Gut Inflammation in Mice Triggers Proliferation and Function of Mucosal Foxp3+ Regulatory T Cells but Impairs Their Conversion from CD4+ T Cells.Colon cancer in inflammatory bowel disease: recent trends, questions and answers.Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis.A challenging case of multiple splenic and pancreatic lesions in a patient with Crohn's disease.Abdominal necrotic abscess from colonic fistula treated endoscopically.CD4+ T cells and Lactobacillus casei control relapsing colitis mediated by CD8+ T cells.Transcutaneous posterior tibial nerve stimulation for fecal incontinence in inflammatory bowel disease patients: a therapeutic option?Butyrate strongly inhibits in vitro stimulated release of cytokines in blood.Is scintigraphic double-track appearance a sign of severe acute episodes of ulcerative colitis?[Chronic active ulcerative colitis. Efficacy of intravenous followed by oral cyclosporine combined with azathioprine].Effects of local corticosteroids on acute experimental urticaria.A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.Urinary neopterin is a valuable tool in monitoring Crohn's disease activity.[Pancytopenia induced by two low-dose injections of methotrexate in a patient treated for ulcerative colitis].Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.Frequency and severity of ileal adenomas in familial adenomatous polyposis after colectomy.Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.Letter: thiopurines - is less really more? Authors' reply.Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial."Comment on a retraction": author response.Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.[Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital].Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.Predictive Models of Therapeutic Response to Vedolizumab: A Novel Step into Personalized Medicine in Crohn's Disease?Long-term disease course in a patient with severe neonatal IPEX syndrome.Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.[Segmentary infarct of the greater omentum: a rare cause of acute abdomen].
P50
Q27021798-5935586E-8C13-45A3-8209-B5A10436002EQ32048109-8815D766-6B4C-480D-BAA9-A2A470707C0DQ33423460-D3E709A5-C531-4089-BA06-0C14F591DF31Q33815262-7DCC9B78-CAEF-4B95-8C07-4EB6B59DCCF3Q35618819-6188A26E-8380-4C31-81C7-E263F4042B7CQ36192570-22E09FD9-6665-454A-88FC-7A4C98FB98F4Q37118466-67FABFB2-EC24-4C4B-8E91-DAFE52D9DFCFQ37387994-F249EA07-039B-42D4-BD6F-11BAFA345511Q38229318-D35951D4-E5A9-4B7A-A27D-C962E0234144Q39077823-8FEF1598-F9FC-43D0-8915-76FE02C15006Q39611339-A140434E-855A-439C-9535-76CBA3FE849FQ39640911-CBE4E3A4-6EE2-4F8A-93AA-014BA16D458CQ39904958-5E0FEE5E-DEFF-4D04-902E-E01BE6E90C01Q40278494-1F69CE5D-0926-4C0A-9FA8-B4E0C7699C99Q41070109-F0F00EF8-9CDA-4360-BF07-D0B47FF5FC05Q41387728-982E51D6-11D1-4EE3-8BCA-22ED961D423CQ43258042-2161EA19-F486-441F-AB13-D25072B261BFQ43365740-D9425F22-3D4F-48F9-A036-49AAA1C4B1C2Q43980803-156E3101-CE3C-4320-9786-35E86D13B0D7Q44849715-78A41109-08A5-4ED4-B85D-A54A5A8C0F58Q44958948-046D75D8-6C18-4A14-8585-0CAB1E5388DBQ45052669-E32CC240-5076-48CF-B41D-02DDA98E7761Q46195773-9AABFFE4-B47F-4DF8-B21F-056F9164676CQ46561227-565095BE-72D9-4295-ACC3-6B071CC95A98Q46822256-734FAB9C-9146-469B-8FE1-DDFDA8610FDDQ47579385-D990AA0F-4620-4F26-888E-AC94F25CE55CQ47747881-6B37E8DC-82FD-4D3A-89F2-EA8FDB677992Q48035026-A445603E-77F9-4E47-92C9-D510D6C72962Q48135457-84C3DDB9-1562-487C-81C3-3A94882C0D47Q48144672-654A2131-62BA-49B1-B33C-9A808A732E11Q48224314-49DB6C87-0B71-4388-AEDF-DA9FC8B78EA5Q49146395-3377D919-3431-4EF7-8709-9E6E2B4AC645Q49185891-BF2DA607-9DC3-4208-840D-C330F173A981Q50872528-331CBC9F-D870-47A0-B0B3-6938580BC232Q51063874-88B534B2-8C01-42DE-BD88-1EABA5B94F34Q51442685-E9BC9A08-CFC0-4ED1-B453-45470C6ADF74Q52580332-96656484-A314-45F7-B19C-D5156360AD11Q53505965-6C4C3356-128B-424C-9E8F-76BA05983BEAQ53572128-C948DBEE-638C-4081-B9CF-86F9BBBAEE76Q53631893-4C840442-AF8A-41E6-9ED2-B731B1238FB7
P50
description
researcher
@en
wetenschapper
@nl
name
Stéphane Nancey
@en
Stéphane Nancey
@nl
type
label
Stéphane Nancey
@en
Stéphane Nancey
@nl
prefLabel
Stéphane Nancey
@en
Stéphane Nancey
@nl
P106
P31
P496
0000-0003-2088-1442